Abstract: A literature review of individuals living with or contracting
Abstract: A literature review of individuals living with or contracting Lyme disease during pregnancy does not support an association with congenital anomalies or adverse pregnancy outcomes provided the patient receives adequate treatment. Currently, the treatment of Lyme disease in pregnant women should not differ from non-pregnant women except tetracyclines, such as doxycycline, are contraindicated and should not be prescribed.
Case Presentation
A 20 year old female, G1P0, at 36 weeks gestation was admitted for evaluation of possible Lyme disease. On admission, she complained of headache, fevers to 102F for two weeks, and numbness, tingling, and weakness in her right thumb, index, and middle fingers with similar symptoms beginning to present in her left hand. She did not observe any dermatologic findings such as an erythema migrans at the site of tick engorgement. Her possible tick exposure was one month earlier and she was found to be positive Transplacental transmission of Lyme disease has been described in several case reports but due to lack of fetal immunologic response there has been little evidence to support an association with congenital anomalies. 6 Similarly, transmission of Lyme disease to a newborn has not been shown to occur by breastfeeding.
Evaluation of a pregnancy that has been complicated by Lyme disease may include examination of the placenta to detect Borellia (spirochetes) within the cord vessel. Additionally, culture, immunohistochemistry staining, and indirect immunofluorescence may be of benefit in determining the presence of Borellia during a pregnancy.
DIAGNOSIS OF LYME DISEASE
The diagnosis (and treatment) of Lyme disease during pregnancy is the same as in the nongravid patient. Although Lyme disease can be diagnosed on a clinical basis if there is evidence of erythema migrans, patients suspected of Lyme disease often undergo laboratory testing. The current gold standard is to first perform an enzymelinked immunosorbent assay (ELISA) which has been associated with a sensitivity of 68-84% and a specificity of 83-100%. Due to the high false positive rates of this test a second confirmatory test is then performed by Western Blot testing to detect antibodies to the organism. Typically, IgM antibodies to B. burgdorferi are present within 2-4 weeks after the tick bite. IgG antibodies appear after 6-8 weeks but unlike the IgM antibodies, the IgG antibodies remain elevated indefinitely. 7 It is important to note that although these tests may indicate the presence of antibodies to this organism they may not be indicative of active disease.
TREATMENT OF LYME DISEASE IN PREGNANCY
The optimal treatment for Lyme disease in pregnant women has not been defined and the Infectious Diseases Society of America has suggested that treatment in pregnant women should not differ from those of non-pregnant women with the exception of doxycycline. 8 Amoxicillin and third generation cephalosporins are safe in pregnant women. If there are neurologic complications as seen in late Lyme infection, IV ceftriaxone for 14-28 days should be used. 1st-degree AV block responds to oral treatment while more serious manifestations require IV treatment. Treatment of women who are seropositive for antibodies to B. burgdorferi at the time of conception is not warranted.
Conclusion
Given the probability for false positives with the screening exam and our patient's negative confirmatory exam the literature would not support giving our patient antibiotics at this time. For future reference, if patients are found to be positive for Lyme disease by Western Blot, amoxicillin 500 mg PO TID for 14 (range 14-21 days) days is recommended. While not first line, macrolides can be given in penicillinallergic individuals. Third generation cephalosporins could be substituted in the event of allergy. Tetracycline and doxycycline are not recommended as they are contraindication during pregnancy.
